Skip to content
Open in App
Roivant Sciences logo

Roivant Sciences

web2

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, de...

Symbol · ROIV
Company profile

About

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves’ disease, difficult-to-treat rheumatoid arthritis, sjögren’s disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company’s lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

FDA approval and United States launch of Lisraya

KEY STEP

The FDA approved Lisraya, or brepocitinib, 30 mg for the treatment of adults with dermatomyositis on August 27, 2026. Roivant and Priovant made the product commercially available immediately, ahead of prior guidance for a launch by the end of September 2026.

Roadmap reference
People

Company team

IO

Ilan Oren

Independent Chairman

Company leadership profile.

MG

Matthew Gline

CEO & Director

Company leadership profile.

MS

Mayukh Sukhatme

President, Chief Investment Officer & Director

Company leadership profile.

DA

Daniel A. Gold

Independent Director

Company leadership profile.

MB

Melissa B. Epperly

Independent Director

Company leadership profile.

KS

Keith S. Manchester

Independent Director

Company leadership profile.

JC

James C. Momtazee

Independent Director

Company leadership profile.

MM

Meghan M. FitzGerald

Independent Director

Company leadership profile.

Expert coverage

1 expert evaluated Roivant Sciences.

Orbitrum research

Experts evaluating Roivant Sciences

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment